Novo Holdings invests £50m in UK-Listed Oxford Nanopore Technologies
Novo Holdings, a leading international life science investor, on Thursday announced a £50m investment in Oxford Nanopore Technologies, the leading UK Listed company behind a new generation of molecular sensing technology based on nanopores.
Oxford Nanopore is developing a transformational new generation of sensing technology that specialises in DNA/RNA sequencing.
The £50m was invested by Novo Holdings as part of an equity issue, with further share purchases expected over time in the secondary market, subject to availability and price.
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo for the treatment of IgA Nephropathy
Calliditas Therapeutics AB announced that the European Commission has granted full marketing authorization for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy (IgAN).
The granting of the full approval results in a significantly broader label for patients with primary IgAN, moving from a urine protein excretion (UPCR) limitation of > 1.5g/g to encompassing the entire study population, defined as UPCR of ≥ 0.8g/g, or proteinuria of ≥1.0 g/g over 24 hours. This expanded label is based on full two-year data set from the Phase 3 NefIgArd clinical trial, published in leading medical journal The Lancet.
Kinpeygo is marketed in the EU and UK exclusively by Calliditas’ commercial partner, STADA Arzneimittel AG.
Countdown to our Conference with Optimum TV
The countdown to Optimum’s Annual Healthcare Investor Conference has begun, with a special Optimum TV mini-series hosted by Optimum’s own Stephen Adams.
In the coming months, Stephen will be chatting to speakers who will be attending the event in October. First up was Kieran Murphy, Chair of Gamma Biosciences, SPT Labtech and Centiva, have a listen to Kieran as he shares his views on the state of play in the life sciences market.
Xeltis is officially on YouTube!
Our client Xeltis this week launched its YouTube channel! Its first video provides an introduction to Xeltis and its Endogenous Tissue Restoration (ETR) technology.
Backed by Nobel-prize winning science, Xeltis’ revolutionary vascular implants could transform the treatment outlook for major life-threatening diseases.
Check out Xeltis’ channel and don’t forget to subscribe for regular updates!
Catch up on the latest life sciences sector moves
Check out the latest moves in the life sciences sector with our monthly round-up of new funds and the biggest job changes, including analysts, bankers, and healthcare journalists.
That’s all folks! We hope you are enjoying Optimum’s weekly round-ups; subscribe on Linkedin today so you never miss an edition.
